NHS South of England Branded Medicines - Tranche A - September 2023
A Contract Award Notice
by NHS ENGLAND
- Source
- Find a Tender
- Type
- Framework (Goods)
- Duration
- not specified
- Value
- £1
- Sector
- HEALTH
- Published
- 14 Aug 2023
- Delivery
- not specified
- Deadline
- n/a
Concepts
Location
United Kingdom: Please refer to Document No. 03, Schedule 8 in the ITO Documents for the list of Purchasing Points
1 buyer
- NHS England Leeds
32 suppliers
- Sandoz Camberley
- Amgen Cambridge
- Accord Barnstaple
- Roche Products Welwyn Garden City
- Teva Castleford
- Abbvie Berks
- Pharmacosmos Berkshire
- Pfizer Sandwich
- Janssen Cilag High Wycombe
- Merck Serono Feltham
- Vifor Pharma London
- Chugai Pharma London
- Novo Nordisk Gatwick
- Merz Hemel Hempstead
- Napp Pharmaceuticals Cambridge
- Orifarm Hemel Hempstead
- Celltrion Healthcare Slough
- Glaxosmithkline London
- Thornton & Ross Huddersfield
- Sun Pharma Uxbridge
- Merck Sharpe & Dohme London
- Astrazeneca London
- Zentiva Pharma London
- Aventis Pharma Berkshire
- Eli Lilly Basingstoke
- Takeda London
- Organon Pharmaceuticals London
- Gedeon Richter London
- Galapagos Biotech Cambridge
- Novartis Pharmaceuticals London
- Sobi Swedish Orphan Biovitrum Cambridgeshire
- Ucb Pharma Slough
Description
NHS South of England Branded Medicines - Tranche A - September 2023Offer reference number: CM/PHR/22/5676CM/PHR/22/5676/01 - NHS Framework for South of England Branded Medicines - Tranche A. Period of framework: 1 September 2023 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.CM/PHR/22/5676/02 - NHS Framework for South of England Branded Medicines - Annual Tranche. Period of framework: 1 September 2023 to 31 August 2024 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months.CM/PHR/22/5676/03 - NHS Framework Agreement for the supply of Risankizumab for the Midlands & East and North of England. Period of framework: 1 September 2023 to 29 February 2024 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months.
Lot Division
| 1 | CM/PHR/22/5676/01 CM/PHR/22/5676/01 - NHS Framework for South of England Branded Medicines - Tranche A. Period of framework: 1 September 2023 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents |
| 2 | CM/PHR/22/5676/02 CM/PHR/22/5676/02 - NHS Framework for South of England Branded Medicines - Annual Tranche. Period of framework: 1 September 2023 to 31 August 2024 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents |
| 3 | CM/PHR/22/5676/03 CM/PHR/22/5676/03 - NHS Framework Agreement for the supply of Risankizumab for the Midlands & East and North of England. … Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents |
Award Detail
| 1 | Sandoz (Camberley)
|
| 2 | Amgen (Cambridge)
|
| 3 | Accord (Barnstaple)
|
| 4 | Roche Products (Welwyn Garden City)
|
| 5 | Teva (Castleford)
|
| 6 | Abbvie (Berks)
|
| 7 | Pharmacosmos (Berkshire)
|
| 8 | Pfizer (Sandwich)
|
| 9 | Janssen Cilag (High Wycombe)
|
| 10 | Merck Serono (Feltham)
|
| 11 | Vifor Pharma (London)
|
| 12 | Chugai Pharma (London)
|
| 13 | Novo Nordisk (Gatwick)
|
| 14 | Merz (Hemel Hempstead)
|
| 15 | Napp Pharmaceuticals (Cambridge)
|
| 16 | Orifarm (Hemel Hempstead)
|
| 17 | Celltrion Healthcare (Slough)
|
| 18 | Glaxosmithkline (London)
|
| 19 | Thornton & Ross (Huddersfield)
|
| 20 | Sun Pharma (Uxbridge)
|
| 21 | Accord (Barnstaple)
|
| 22 | Roche Products (Welwyn Garden City)
|
| 23 | Merck Sharpe & Dohme (London)
|
| 24 | Teva (Castleford)
|
| 25 | Astrazeneca (London)
|
| 26 | Zentiva Pharma (London)
|
| 27 | Abbvie (Berks)
|
| 28 | Pfizer (Sandwich)
|
| 29 | Aventis Pharma (Berkshire)
|
| 30 | Janssen Cilag (High Wycombe)
|
| 31 | Eli Lilly (Basingstoke)
|
| 32 | Takeda (London)
|
| 33 | Organon Pharmaceuticals (London)
|
| 34 | Gedeon Richter (London)
|
| 35 | Galapagos Biotech (Cambridge )
|
| 36 | Novartis Pharmaceuticals (London)
|
| 37 | Sobi Swedish Orphan Biovitrum (Cambridgeshire)
|
| 38 | Ucb Pharma (Slough)
|
Award Criteria
| price | _ |
CPV Codes
- 33600000 - Pharmaceutical products
Indicators
- Options are available.
Other Information
** PREVIEW NOTICE, please check Find a Tender for full details. **
Reference
- ocds-h6vhtk-03ae6d
- FTS 023735-2023